Introgen Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. We are developing product candidates to treat a wide range of cancers using tumor suppressors, cytokines and other targeted molecular agents. Our products are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells, stimulate immune activity, or directly kill cancer cells. Introgen's therapies can be used alone, but also enhance conventional cancer therapies such as surgery, chemotherapy, radiation and monoclonal antibodies.
Our drug discovery and development programs have resulted in innovative approaches by which physicians may use targeted molecular agents to more precisely treat cancer. Introgen's low-toxicity approach to cancer treatment has drawn global interest from oncologists